C7R-GD2.CART cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameC7R-GD2.CART cells
Drug Alias NameC7R-EBV T cellanti-GD2 CAR T-cell therapy (Baylor College of Medicine/Texas Children's Hospital)anti-GD2 CAR/constitutive IL-7 signaling T cell therapy (Baylor College of Medicine/Texas Children's Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionDisialoganglioside GD2 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastomaGlioblastomaGlioma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesTexas Children'S HospitalBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsNeuroblastomaGlioblastomaGlioma +[6] 
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A